Cover Image

Expression of ERK1 and ERK2 in prostate cancer

Norelia Torrealba, Benito Fraile, Gabriel Olmedilla, Pilar Martínez-Onsurbe, Manuel Guil-Cid, Ricardo Paniagua, Mar Royuela
  • Norelia Torrealba
    Department of Biomedicine and Biotechnology, University of Alcalá, Madrid, Spain
  • Benito Fraile
    Department of Biomedicine and Biotechnology, University of Alcalá, Madrid, Spain
  • Gabriel Olmedilla
    Department of Pathology, Príncipe de Asturias Hospital, Alcalá de Henares, Madrid, Spain
  • Pilar Martínez-Onsurbe
    Department of Pathology, Príncipe de Asturias Hospital, Alcalá de Henares, Madrid, Spain
  • Manuel Guil-Cid
    Department of Urology, Príncipe de Asturias Hospital, Alcalá de Henares, Madrid, Spain
  • Ricardo Paniagua
    Department of Biomedicine and Biotechnology, University of Alcalá, Madrid, Spain
  • Mar Royuela
    Department of Biomedicine and Biotechnology, University of Alcalá, Madrid, Spain | mar.royuela@uah.es

Abstract

Prostate cancer may emerge as result of dysregulated balance between cell proliferation and death rates, increased angiogenesis and chronic. These processes are regulated by numerous signaling proteins, including the mitogen-activated protein kinases (MAPKs). JNK, p38 and extracellular signal-regulated kinase (ERK) are the three major sub-families of MAPKs. The pro-oncogenic effects of ERK isoforms (ERK1 and ERK2) lie in their aberrant activation through phosphorylation by any mutation along the pathway of receptor tyrosine kinase (RTK)-Ras-Raf-MEK-ERK1/2. Once activated, ERKs phosphorylate cytoskeletal proteins, kinases, and transcription factors. Active ERK proteins induce strong proliferative and anti-apoptotic effects. Our group has tested variations in expression, activation and localization of ERKs in human prostate. Differential ERK1/2 expression and phosphorylation status may be linked to the progression of prostate cancer. The major striking observation is that ERKs are expressed in tumors with higher proportion than normal prostate. We believe that this is an important notion because the status (expression, localization, phosphorylation and the ERK1/ERK2 ratio) of ERK in the prostate may be developed into an important prognostic marker that predicts patient responce to the anti-cancer treatment.

Keywords

MAPKs; ERK1; ERK2; p-ERK and prostate cancer.

Full Text:

PDF
Submitted: 2015-05-12 15:00:27
Published: 2015-12-18 18:23:47
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
1714

Views:
PDF
285

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2015 Norelia Torrealba, Benito Fraile, Gabriel Olmedilla, Pilar Martínez-Onsurbe, Manuel Guil-Cid, Ricardo Paniagua, Mar Royuela

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185